Allendale Pharmaceuticals Today Sponge
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Proposed labeling for the nonoxynol-9 contraceptive sponge adequately explains that the sponge does not provide full protection from STDs and AIDS and sufficiently describes risks of toxic shock syndrome, FDA's Nonprescription Drugs Advisory Committee agrees July 12. The committee voted in favor of including comparative contraceptive efficacy information on the outer package of the OTC sponge. Allendale is attempting to re-market the sponge, which the company acquired from American Home Products in 1998. AHP had discontinued sale of the product due to quality control problem
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.